Understanding Doxorubicin Resistance in Rat Glioblastoma Cells
Author Information
Author(s): S. Huet, B. Schott, J. Robert
Primary Institution: Fondation Bergonie and Universite de Bordeaux II
Hypothesis
Can classical multidrug resistance explain the complete resistance phenotype in doxorubicin-resistant rat glioblastoma cells?
Conclusion
The study suggests that classical multidrug resistance cannot fully explain the resistance observed in the most resistant glioblastoma cell lines.
Supporting Evidence
- Three resistant variants of the C6 glioblastoma cell line were studied.
- Doxorubicin resistance was found to be 7, 33, and 400-fold in different cell variants.
- Verapamil was shown to reverse drug incorporation in resistant cell lines.
Takeaway
Some cancer cells can become resistant to a drug called doxorubicin, and this study found that just one reason for this resistance isn't enough to explain it all.
Methodology
The study involved pharmacological studies and semi-quantitative evaluation of P-glycoprotein expression in various doxorubicin-resistant cell lines.
Limitations
The study does not explore all potential mechanisms of resistance beyond P-glycoprotein.
Want to read the original?
Access the complete publication on the publisher's website